Roza I. Nurieva, Ph.D.
Department of Immunology, Division of Discovery Science
About Dr. Roza I. Nurieva
Dr. Roza Nurieva is a Professor in the Department of Immunology at The University of Texas MD Anderson Cancer Center. Research in her laboratory aims to elucidate the molecular basis of T cell mediated immune responses, and how abnormal immune regulation leads to immunodeficiency, autoimmunity and cancer. In recent work, Dr. Nurieva’s laboratory showed that transplantation of Grail-deficient T cells into a mouse model of lymphoma was sufficient to inhibit the growth of established tumors, suggesting Grail is a potential target to improve the cancer immune response. Continuing studies will help us to understand the function of the immune system, and will, therefore, help develop approaches to design drugs against cancer, as well as against autoimmune disorders.
Present Title & Affiliation
Primary Appointment
Professor, Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
Member, Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences (GSBS), Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Tenured, Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
Member, Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences (GSBS), Houston, TX
Education & Training
Degree-Granting Education
| 1999 | Pushchino State University, Moscow, RU, Immunology & Biochemistry, Ph.D |
| 1996 | Pushchino State University, Pushchino, RU, Biology, M.S |
| 1994 | Kazan State University, Kazan, RU, Biochemistry, B.S |
Postgraduate Training
| 2001-2004 | Postdoctoral Fellowship, Immunology, University of Washington, Seattle, Washington |
Experience & Service
Faculty Academic Appointments
Associate Professor, Tenured, Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2023
Assistant Professor, Tenure-Track, Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2017
Assistant Professor, Non-Tenure Track, Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2011
Instructor, Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2008
Senior Fellow, Immunology, University of Washington, Seattle, WA, 2001 - 2004
Research Scientist, Branch of S & O, Institute of Bioorganic Chemistry, Pushchino, 1999 - 2000
Other Professional Positions
Chair, Odyssey, The University of Texas MD Anderson Cancer Center, Houston, TX, 2025 - Present
Co-Chair, Odyssey, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - 2025
Co-Chair, Immunology Cluster Steering Committee, Gulf Coast Consortium (GCC), Houston, TX, 2022 - Present
Co-Organizer, Immunology Department Seminars, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - 2024
Tenure Review Evaluation Committee, Okinawa Institute of Science and Technology Graduate University, Kunigami District, 2019
Consultant, Nurix, Inc, San Francisco, CA, 2018 - 2019
Responsible for Organization of Joint Laboratory Meetings, Host for Speakers, The University of Texas MD Anderson Cancer Center, Center for Inflammation and Cancer (CIC), Houston, TX, 2013 - 2021
Extramural Institutional Committee Activities
Departmental Wellness Advocate, Departmental Wellness Advocate (DA), The University of Texas MD Anderson Cancer Center, 2025 - Present
Representative, Department of Immunology, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Committee Member, Odyssey Fellowship Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Immunology Education and Training Representative, Cancer Center Support Grant (CCSG), The University of Texas MD Anderson Cancer Center, 2022 - Present
Advisory Committee, Breeder Animal Moves, The University of Texas MD Anderson Cancer Center, 2020 - Present
Faculty Mentor, Graduate School of Biomedical Sciences (GSBS) Immunology Retreat Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2023
Interviewer, Graduate School of Biomedical Sciences (GSBS) Applicants, The University of Texas MD Anderson Cancer Center, 2020 - 2023
Faculty Search Committee Member, Anesthesiology & Perioperative Medicine, Division of Anesthesiology, Critical Care & Pain Medicine, The University of Texas MD Anderson Cancer Center, 2019 - 2021
Committee Member, Graduate School of Biomedical Sciences (GSBS) Academic Standards Committee (ASC), The University of Texas MD Anderson Cancer Center, 2018 - Present
Committee Member, Institutional Animal Care and Use Committee (IACUC), The University of Texas MD Anderson Cancer Center, 2018 - 2023
Member, Graduate School of Biomedical Sciences (GSBS) Admission Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Member, Income Advisory Meeting, The University of Texas MD Anderson Cancer Center, Annual Department of Veterinary Medicine and Surgery (DVMS) Program, The University of Texas MD Anderson Cancer Center, 2012 - Present
Member, Animal Research Infrastructure Strategic Planning Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2017
Editorial Activities
Editor of Research Topic: Cancer Immunotherapy – Diagnostic and Therapeutic Strategies to Enhance Antitumoral Efficacies Whilst Minimizing Toxicity, Frontiers in Immunology, 2022 - Present
Guest Associate Editor, Frontiers in Immunology, Cancer Immunity and Immunotherapy, 2021 - Present
Review Editor, Frontiers in Immunology, 2019 - Present
Member of Editorial Review Board, Journal of Immunology Research and Therapy, 2016 - Present
Member of Editorial Review Board, Journal of Clinical and Cellular Immunology, 2010 - Present
Honors & Awards
| 2024 | Travel Award, International Cytokine & Interferon Society (ICIS) |
| 2020 | President’s Recognition of Faculty Excellence in Research Excellence, The University of Texas MD Anderson Cancer Center |
| 2020 | Milstein Abstract Award, International Cytokine & Interferon Society (ICIS) |
| 2019 | American Association of Immunologists (AAI) Careers in Immunology Fellowship, American Association of Immunologists (AAI) |
| 2018 | American Association of Immunologists (AAI) Laboratory Travel Grant, American Association of Immunologists (AAI) |
| 2018 | American Association of Immunologists (AAI) Careers in Immunology Fellowship, American Association of Immunologists (AAI) |
| 2015 | The Journal of Biological Chemistry/Herbert Tabor Young Investigator Award, International Cytokine and Interferon Society (ICIS) |
| 2015 | American Association of Immunologists (AAI) Travel Award Grant for the 4th European Congress of Immunology, American Association of Immunologists (AAI) |
| 2014 - 2018 | Top 1% of Highly Cited Researchers, Thomson Reuters |
| 2010 | Travel Award Grant, 14th International Congress of Immunology, American Associations of Immunologists (AAI) |
| 2010 | Pfizer-Showell Travel Award, American Association of Immunologists (AAI)/Henry J. Showell and Pfizer, Inc |
| 2009 - 2012 | Junior Faculty Travel Grant, American Association of Immunologists (AAI) |
| 2008 | BioSymposia Young Investigator Travel Award |
| 2007 | Arthritis Foundation Travel Award, Arthritis Foundation |
| 2006 - 2009 | Scientist Development Grant, American Heart Association (AHA) |
| 2005 | Arthritis Foundation Travel Award, Arthritis Foundation |
| 2004 | Federation of Clinical Immunology Societies Centers of Excellence Trainee Satellite Symposium Travel Grant |
| 2003 - 2006 | Arthritis Foundation Postdoctoral Fellowship, Arthritis Foundation |
| 1990 - 2000 | International Soros Science Education Program |
| 1989 | International Soros Science Education Program |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. The influence of sex and age on tumor outcomes. Invited. Anaplastic Thyroid Cancer (ATC) Research Meeting. Houston, Texas, US.
- 2025. Molecular and immune hallmarks of inflammatory arthritis induced by checkpoint inhibitor therapy. Invited. Division of Internal Medicine Research Grand Rounds, US.
- 2024. Preclinical models for the investigation of immune-mediated colitis. 2024 IOTOX Symposium: Treating Immune-Related Adverse Events: Integrating Insights from Clinical, Translational and Basic Science. Houston, Texas, US.
- 2024. Preclinical models of irAE: mechanistic insights and potential targets. Division of Internal Medicine Research Grand Rounds. Houston, Texas, US.
- 2024. Sex and Age Bias in ATC: Interplay between immunity and microbiome. Anaplastic Thyroid Cancer (ATC) Research Meeting. Houston, Texas, US.
- 2024. Role of Tfh cells in anti-tumor immunity. Melanoma Research Seminar Series. Houston, Texas, US.
- 2024. Shaping the tumor immune microenvironment: mechanisms and inflammatory complications. James P. Allison Institute Seminars. Houston, Texas, US.
- 2020. Elucidation of mechanisms underlying immune checkpoint inhibitor-induced arthritis. Conference. Elucidation of mechanisms underlying immune checkpoint inhibitor-induced arthritis. Houston, TX, US.
National Presentations
- 2025. Mechanistic insights on immune checkpoint inhibitor-induced recurrent inflammatory arthritis. Invited. American Association of Immunologists (AAI). Honolulu, Hawaii, US.
- 2024. Preclinical models of irAE: mechanistic insights and potential targets. Conference. American Association of Immunologists (AAI). Chicago, IL, US.
- 2018. Role of E3 ubiquitin ligase GRAIL in B cell activation and tolerance. Conference. Role of E3 ubiquitin ligase GRAIL in B cell activation and tolerance. Austin, TX, US.
- 2017. Absence of grail promotes CD8+ T cell anti-tumor activity. Conference. Chicago, IL, US.
- 2017. Absence of Grail promotes CD8+ T cell anti-tumor activity. Conference. Global Academic Programs (GAP) Young Investigators Workshop. Houston, TX, US.
- 2016. Grail: T cell tolerance in cancer. Conference. Houston, TX, US.
- 2012. STAT5 controls Tfh development. Conference. American Association of Immunologists (AAI). Boston, MA, US.
- 2011. Regulation of naive T cell tolerance and regulatory T cell function by GRAIL. Conference. American Association of Immunologists (AAI). San Francisco, CA, US.
- 2010. A critical role of GRAIL in T cell activation and tolerance. Conference. 97th Annual Meeting of the American Association of Immunologists (AAI). Baltimore, MD, US.
- 2009. Developmental requirements of T follicular helper cell. Conference. Atlanta, GA, US.
- 2009. Developmental requirements of T follicular helper cell. Conference. 96th Annual Meeting of the American Association of Immunologists (AAI). Seattle, WA, US.
- 2008. Regulation of T follicular helper cell development. Conference. La Jolla, CA, US.
International Presentations
- 2024. Immune checkpoint inhibitor mediated colitis: mechanistic insights and potential targets. Conference. 12th Annual Meeting of the International Cytokine & Interferon Society (ICIS) (Cytokines 2024). Seoul, KR.
- 2023. Inflammatory arthritis induced by immune checkpoint inhibitors: underlying mechanisms and therapeutic strategies. Conference. 11th Annual Meeting of the International Cytokine & Interferon Society (ICIS) (Cytokines 2023). Houston, US.
- 2023. Mechanism underlying immune-related adverse events (irAEs) in cancer patients receiving ICI therapy. Conference. 4th International Conference on Cell and Experimental Biology. Houston, US.
- 2019. Role of Tfh cells in the antitumor immunity, symposium. Conference, CN.
- 2018. Role of E3 ubiquitin ligase GRAIL in B cell activation and tolerance. Conference. Role of E3 ubiquitin ligase GRAIL in B cell activation and tolerance. Dresden, DE.
- 2017. STAT1 is required for Tfh lineage maintenance through regulation of IL-21 expression. Conference. Whistler, CA.
- 2015. Transcriptional regulation of IL-4 expression in T follicular helper T cells. Conference. Annual Meeting of International Cytokine Society (ICS). Bamberg, DE.
- 2015. BATF is essential for IL-4 expression in T follicular helper cells. Conference. Houston, US.
- 2014. Regulation of Th2 cell responses by Grail. Conference. Melbourne, AU.
- 2013. Factors that regulate Tfh cells. Conference. The Chinese University of Hong Kong. Hong Kong, CN.
- 2007. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Conference. San Francisco, US.
- 2004. Regulation of immune and autoimmune responses by ICOS-B7h interaction. Conference. Montreal, CA.
Formal Peers
- 2022. Tfh-based immunotherapy of melanoma. Invited. Houston, TX, US.
- 2021. Grail and immune tolerance. Invited. Pittsburgh, PA, US.
- 2021. Mechanisms of immune tolerance. Invited. Albuquerque, NM, US.
- 2021. E3 ligases and immune tolerance. Invited. Houston, TX, US.
- 2019. Grail: the key regulator of T and B cell tolerance. Invited, SG.
- 2019. Grail: the key regulator of peripheral tolerance. Invited. North Chicago, IL, US.
- 2019. Role of Grail in T and B cell activation and tolerance. Invited. Houston, TX, US.
- 2016. Role of Grail in T cell activation and function. Invited. College Station, TX, US.
- 2015. Barf is essential for IL-4 expression in T follicular helper cells. Invited. Detroit, MI, US.
- 2015. Transcriptional control of IL-4 expression in T follicular helper cells. Invited. Norfolk, VA, US.
- 2014. Role of GRAIL in T cell function. Invited. Galveston, TX, US.
- 2013. E3 ubiquitin ligases in T cell tolerance. Invited. Tyler, TX, US.
- 2009. A critical role of GRAIL in T cell activation and tolerance. Invited. Atlanta, GA, US.
- 2008. Regulation of T follicular helper cell development. Invited. La Jolla, CA, US.
Grant & Contract Support
| Date: | 2027 - 2029 |
| Title: | Role of the Pro-Inflammatory Omental Microenvironment in Ovarian Cancer Progression |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | FP00012135_Res1_Rev2 |
| Date: | 2027 - 2032 |
| Title: | Modulating GSDMB Splicing to Trigger Antitumor Pyroptosis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA311267-01A1 |
| Date: | 2027 - 2032 |
| Title: | The Role of B Cells in the Onset of Immune Checkpoint Inhibitor-Mediated Colitis |
| Funding Source: | NIH |
| Role: | PI |
| ID: | 1R01CA322448-01 |
| Date: | 2027 - 2032 |
| Title: | Role of a Novel Omentum-Derived Adipokine in Modulating Endometrial Cancer Development and Progression |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00030474 |
| Date: | 2027 - 2029 |
| Title: | Redefining Treatment: Novel Strategies for Anaplastic Thyroid Cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00029409 |
| Date: | 2026 - 2029 |
| Title: | Nanosecond Pulsed Field Ablation for Treating Aggressive Thyroid Cancers |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | FP00029959 |
| Date: | 2026 - 2029 |
| Title: | B Cells as Predictive Biomarkers for the Risk of Immune Checkpoint Therapy Associated Colitis |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | RP 270406 |
| Date: | 2026 - 2031 |
| Title: | ImpACT: Improving Treatment Strategies for Anaplastic Thyroid Cancer Through Integration of Novel Therapies and Assessment of Tumor Response |
| Funding Source: | NIH/NCI |
| Role: | Co-Project Lead |
| ID: | 1P01CA314921-01A1 |
| Date: | 2025 - 2029 |
| Title: | Role of GRAIL in B Cell Tolerance and B-Cell Mediated Inflammation |
| Funding Source: | NIH/NIAID |
| Role: | PI |
| ID: | 1R01AI183604-01A1; Project: 00018040 |
| Date: | 2025 - 2027 |
| Title: | Chimeric RNA Driven Neopeptide Vaccine for Prevention of Breast Cancer in Germline BRCA1/2 Carriers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5UG3CA290454-02; Project: 00018027 |
| Date: | 2025 - 2027 |
| Title: | Role of Cytokines in ICI-Colitis |
| Funding Source: | Waldman Family Fund |
| Role: | PI |
| ID: | Fund: 129202 |
| Date: | 2024 - 2027 |
| Title: | Role of Grail in Colon Inflammation and Tumorigenesis |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5R03CA286624-03; Project: 00016431 |
| Date: | 2024 - 2025 |
| Title: | Role of GRAIL in B Cell Tolerance and B-Cell Mediated Inflammation |
| Funding Source: | The University of Texas MD Anderson Cancer Center – Bridge Funding |
| Role: | PI |
| ID: | 2024-00063609-Y1 |
| Date: | 2023 - 2024 |
| Title: | Elucidation of Mechanisms underlying Inflammatory Arthritis Induced by Immune Checkpoint Inhibitors and Development of the Mechanism-Rooted Therapeutic Strategy |
| Funding Source: | Yale University |
| Role: | PI |
| ID: | FF2024-00063348-WC |
| Date: | 2023 - 2028 |
| Title: | Mechanism-Rooted Therapeutic Strategies for Immune-Related Toxicities Induced by Checkpoint Inhibitors |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5R01CA284684-04; Project: 00015169 |
| Date: | 2023 - 2024 |
| Title: | Tfh cell-based adoptive cell therapy for melanoma |
| Funding Source: | The University of Texas MD Anderson Cancer Center - SPORE in Melanoma Cancer - Developmental Research Program (DRP) |
| Role: | PI |
| ID: | FP00019948 |
| Date: | 2022 - 2023 |
| Title: | Elucidation of mechanisms underpinning arthritis associated with immune checkpoint inhibitor therapy with preclinical murine model |
| Funding Source: | The University of Texas MD Anderson Cancer Center – Melanoma SPORE - Developmental Research Program (DRP) |
| Role: | PI |
| ID: | RCTS 00061371; Fund: 124970 |
| Date: | 2022 - 2023 |
| Title: | Elucidation of mechanisms underlying colitis associated with immune checkpoint inhibitor therapy |
| Funding Source: | The University of Texas MD Anderson Cancer Center - SPORE in Gastrointestinal Cancer - Developmental Research Program (DRP) |
| Role: | PI |
| ID: | FP00016495; Fund: 125344 |
| Date: | 2022 - 2023 |
| Title: | Mechanisms underlying immune checkpoint inhibitor associated colitis in melanoma patients |
| Funding Source: | Linda and Mark Quick |
| Role: | PI |
| ID: | Fund: 124688 |
| Date: | 2022 - 2027 |
| Title: | Role of the Pro-Inflammatory Omental Microenvironment in Ovarian Cancer Progression |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5R37CA261952-04; Project: 00014122 |
| Date: | 2022 - 2025 |
| Title: | Underlying mechanisms and management of ICI-induced arthritis for melanoma patients |
| Funding Source: | The University of Texas MD Anderson Cancer – Internal Research Grant (IRG) |
| Role: | PI |
| ID: | RCTS 00060699 |
| Date: | 2021 - 2023 |
| Title: | Characterization of altered immunity in patients with inflammatory arthritis induced by immune checkpoint inhibitor therapy |
| Funding Source: | NIH/NIAMS |
| Role: | Primary Mentor |
| ID: | 5K08AR079587-02 |
| Date: | 2020 - 2021 |
| Title: | Underlying mechanisms and management of ICI-induced arthritis in melanoma patients |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Melanoma SPORE Developmental Research Program (DRP) |
| Role: | PI |
| ID: | 00058651 |
| Date: | 2019 - 2024 |
| Title: | Arthritis-related (mouse and human) experiments |
| Funding Source: | The University of Texas MD Anderson Cancer Center – Wilkes Fund |
| Role: | PI |
| ID: | Fund: 122096 |
| Date: | 2019 - 2023 |
| Title: | Therapeutic potential of T follicular helper cells for melanoma treatment |
| Funding Source: | Cancer Prevention and Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP190326 |
| Date: | 2019 - 2024 |
| Title: | Role of E3 ubiquitin ligase RNF133 in T cell function and tolerance |
| Funding Source: | NIH/NHLBI |
| Role: | PI |
| ID: | 5R01HL141966-04 |
| Date: | 2018 - 2019 |
| Title: | Function of T follicular helper cells in anti-tumor immunity |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R03CA235009-01 |
| Date: | 2018 - 2024 |
| Title: | Role of Cul4A in governing Th2-type tolerance |
| Funding Source: | NIH/NHLBI |
| Role: | PI |
| ID: | 5R01HL143520-04; Project: 00006906 |
| Date: | 2018 - 2021 |
| Title: | Isoform-specific targeting of the PI3Ks to overcome cancer immunoresistance |
| Funding Source: | Melanoma Research Alliance |
| Role: | Collaborator |
| ID: | 558998 |
| Date: | 2018 - 2019 |
| Title: | Careers in immunology fellowship - role of T follicular helper cells in anti-tumor immunity |
| Funding Source: | American Association of Immunologists (AAI) |
| Role: | PI |
| Date: | 2018 - 2024 |
| Title: | B cell anergy, acLDL uptake and atherosclerosis |
| Funding Source: | NIH/NHLBI (Sub with Eastern Virginia Medical School) |
| Role: | Principal Investigator-MDACC |
| ID: | 5R01HL139000-04; Project: 00006437 |
| Date: | 2017 - 2021 |
| Title: | Grail-targeting breaks the immune tolerance to melanoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5R03CA219760-02 |
| Date: | 2017 - 2019 |
| Title: | Role of Cul4A in Th2 tolerance and airway inflammation |
| Funding Source: | NIH/NIAID |
| Role: | PI |
| ID: | 1R56AI125269-01A1 |
| Date: | 2016 - 2020 |
| Title: | Therapeutic potential of follicular helper T cells for melanoma treatment |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Institutional Research Grant (IRG) |
| Role: | PI |
| ID: | 2016-00053042-Y1 |
| Date: | 2016 - 2017 |
| Title: | The role and regulation of follicular helper T cells in tumor immunity |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Melanoma SPORE Career Development (CDA) |
| Role: | PI |
| ID: | 2016-00053060-Y1 |
| Date: | 2016 - 2017 |
| Title: | The role of regulation of follicular T cells in tumor immunity |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Melanoma SPORE Career Development Award (CDA) |
| Role: | PI |
| Date: | 2016 - 2018 |
| Title: | STAT1: new regulator of inflammatory Th17 and Th2 cells |
| Funding Source: | NIH/NIAID |
| Role: | PI |
| ID: | 5R21AI20012-02 |
| Date: | 2015 - 2019 |
| Title: | Enhancing anticancer T cell reactivity by targeting grail |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Bridge Funding |
| Role: | PI |
| ID: | 2016-00051130-Y2 |
| Date: | 2015 - 2024 |
| Title: | Role of T follicular helper cells in anti-tumor immunity |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Center for Inflammation and Cancer (CIC) |
| Role: | PI |
| ID: | 2015-13015459-Y1; Fund: 115274 |
| Date: | 2015 - 2018 |
| Title: | Role of grail in maintaining humoral immune tolerance |
| Funding Source: | NIH/NIAID |
| Role: | PI |
| ID: | 5R03AI120027-02 |
| Date: | 2014 - 2016 |
| Title: | Regulation of T cell activation and function by Cul4A |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Institutional Research Grant (IRG) |
| Role: | PI |
| Date: | 2013 - 2023 |
| Title: | Grail deficiency promotes intestinal inflammation and cancer development |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Center for Inflammation and Cancer (CIC) |
| Role: | PI |
| ID: | Fund: 12243 |
| Date: | 2013 - 2016 |
| Title: | Effector and memory T follicular helper cells |
| Funding Source: | NIH/NIAID |
| Role: | Co-I |
| ID: | 5R01AI106654-02 |
| Date: | 2012 - 2014 |
| Title: | The role of complement system in alloimmune responses |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5R21AI101932-02 |
| Date: | 2011 - 2023 |
| Title: | Start-up funds |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2009 - 2011 |
| Title: | Transcriptome and epigenome analysis of helper T cell specification and plasticity |
| Funding Source: | NIH/NIAMS |
| Role: | Co-PI |
| ID: | 1RC2AR59010-01 |
| Date: | 2009 - 2014 |
| Title: | Regulation of T cell activation and tolerance by grail |
| Funding Source: | NIH/NIAID |
| Role: | PI |
| ID: | 5R01AI083761-04 |
| Date: | 2006 - 2009 |
| Title: | The role of ICOS-B7h in atherosclerosis |
| Funding Source: | American Heart Association |
| Role: | PI |
| Date: | 2003 - 2006 |
| Title: | ICOS-B7h interaction in humoral immunity and rheumatoid arthritis |
| Funding Source: | Arthritis Foundation |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Houl, J, Yarmand, R, Kunnimalaiyaan, M, Miranda Mendez, P, Kidd, JL, Dadbin, A, Ruiz-Jurado, A, Parekh, PA, Henderson, Y, Chari, N, Thennavan, A, Powell, RT, Stephan, C, Zhao, X, Maniakas, A, Nurieva, R, Busaidy, NL, Cabanillas, ME, Dadu, R, Zafereo, M, Wang, RJ, Lai, SY, Hofmann, M. Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells. Molecular cancer therapeutics 25(5):844-859, 2026. e-Pub 2026. PMID: 41544239.
- Imanishi, M, Samanthapudi, VS, Le, NT, Rivera, LA, Kim, JH, Lee, J, Mejia, G, Hoang, ON, Deswal, A, Schadler, KL, Hildebrandt, MA, Yusuf, SW, Wang, G, Burks, JK, Nurieva, R, Palaskas, NL, Nead, KT, Amir, ED, Koutroumpakis, E, Lin, SH, Abe, J, Kotla, S. Ionizing radiation expands a p90RSK-activated patrolling monocyte subset. Frontiers in Cardiovascular Medicine 13, 2026. e-Pub 2026. PMID: 42064851.
- Houl JH, Bagheri-Yarmand R, Kunnimalaiyaan M, Miranda Mendez P, Kidd JL, Dadbin A, Jurado Ruiz A, Parekh PA, Henderson YC, Chari NS, Thennavan AT, Powell RT, Stephan CC, Zhao X, Maniakas A, Nurieva R, Busaidy NL, Cabanillas ME, Dadu R, Zafereo M, Wang JR, Lai SY, Hofmann MC. Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cells. bioRxiv, 2025. e-Pub 2025. PMID: 40027641.
- Keam S, Tuner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, Alekseev S, Patel AB, Li YJ, Sheshadri A, Loghin ME, Woodman K, Aaroe AE, Hamidi S, Iyer PC, Palaskas NL, Wang Y, Nurieva RI. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol 15, 2024. e-Pub 2024. PMID: 39247203.
- Lu L, Wang JR, Henderson YC, Bai S, Yang J, Hu M, Shiau CK, Pan T, Yan Y, Tran TM, Li J, Kieser R, Zhao X, Wang J, Nurieva R, Williams MD, Cabanillas ME, Dadu R, Busaidy NL, Zafereo M, Navin N, Lai SY, Gao R. Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics. J Clin Invest 133(11):e169653, 2023. e-Pub 2023. PMID: 37053016.
- Soto F, Torre-Sada LF, Mott FE, Kim ST, Nurieva R, Shannon VR, Faiz SA, Casal RF, Altan M, Lin J, Sheshadri A. Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy. J Immunother Precis Oncol 6(2):111-116, 2023. e-Pub 2023. PMID: 37214206.
- Imanishi M, Cheng H, Kotla S, Deswal A, Le NT, Chini E, Ko KA, Samanthapudi VSK, Lee LL, Herrmann J, Xu X, Reyes-Gibby C, Yeung SJ, Schadler KL, Yusuf SW, Liao Z, Nurieva R, Amir ED, Burks JK, Palaskas NL, Cooke JP, Lin SH, Kobayashi M, Yoshimoto M, Abe JI. Radiation therapy induces immunosenescence mediated by p90RSK. Front Cardiovasc Med 9:988713, 2022. e-Pub 2022. PMID: 36426217.
- Xu T, Wu L, Gandhi S, Jing W, Nguyen QN, Chen A, Chang JY, Nurieva R, Sheshadri A, Altan M, Lee PP, Lin SH, Liao Z. Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer. Radiother Oncol 176:149-156, 2022. e-Pub 2022. PMID: 36209942.
- Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40(5):509-523.e6, 2022. e-Pub 2022. PMID: 35537412.
- Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
- Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol 11:590494, 2021. e-Pub 2021. PMID: 33552049.
- Yang XO, Angkasekwinai P, Zhu J, Peng J, Liu Z, Nurieva R, Liu X, Chung Y, Chang SH, Sun B, Dong C. Author Correction: Requirement for the basic helix-loop-helix transcription factor Dec2 in initial TH2 lineage commitment. Nat Immunol 21(11):1467, 2020. e-Pub 2020. PMID: 32884131.
- Tanaka S, Tanaka K, Magnusson F, Chung Y, Martinez GJ, Wang YH, Nurieva RI, Kurosaki T, Dong C. Correction: CCAAT/Enhancer-Binding Protein α Negatively Regulates IFN-γ Expression in T Cells. J Immunol 205(8):2322, 2020. e-Pub 2020. PMID: 32929039.
- Yeonseok C, Roza N, Eiji E, Yi-Hong W, Dapeng Z, Laurent G, Chen D. Correction: A critical role of costimulation during intrathymic development of invariant NK T cells. J Immunol 205(8):2321, 2020. e-Pub 2020. PMID: 32938728.
- Kim ST, Bittar M, Kim HJ, Neelapu SS, Zurita AJ, Nurieva R, Suarez-Almazor ME. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. J Immunother Cancer 7(1):126, 2019. e-Pub 2019. PMID: 31088575.
- Liu X, Wang Y, Lu H, Li J, Yan X, Xiao M, Hao J, Alekseev A, Khong H, Chen T, Huang R, Wu J, Zhao Q, Wu Q, Xu S, Wang X, Jin W, Yu S, Wang Y, Wei L, Wang A, Zhong B, Ni L, Liu X, Nurieva R, Ye L, Tian Q, Bian XW, Dong C. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. Nature 567(7749):525-529, 2019. e-Pub 2019. PMID: 30814730.
- Khosravi N, Caetano MS, Cumpian AM, Unver N, De la Garza Ramos C, Noble O, Daliri S, Hernandez BJ, Gutierrez BA, Evans SE, Hanash S, Alekseev AM, Yang Y, Chang SH, Nurieva R, Kadara H, Chen J, Ostrin EJ, Moghaddam SJ. IL22 Promotes Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Stemness Properties. Cancer Immunol Res 6(7):788-797, 2018. e-Pub 2018. PMID: 29764837.
- Na H, Lim H, Choi G, Kim BK, Kim SH, Chang YS, Nurieva R, Dong C, Chang SH, Chung Y. Concomitant suppression of TH2 and TH17 cell responses in allergic asthma by targeting retinoic acid receptor-related orphan receptor γt. J Allergy Clin Immunol 141(6):2061-2073, 2018. e-Pub 2018. PMID: 28943467.
- Taghavie-Moghadam PL, Waseem TC, Hattler J, Glenn LM, Dobrian AD, Kaplan MH, Yang Y, Nurieva R, Nadler JL, Galkina EV. STAT4 Regulates the CD8+ Regulatory T Cell/T Follicular Helper Cell Axis and Promotes Atherogenesis in Insulin-Resistant Ldlr-/- Mice. J Immunol 199(10):3453-3465, 2017. e-Pub 2017. PMID: 29055004.
- Cheekatla SS, Tripathi D, Venkatasubramanian S, Paidipally P, Welch E, Tvinnereim AR, Nurieva R, Vankayalapati R. IL-21 Receptor Signaling Is Essential for Optimal CD4+ T Cell Function and Control of Mycobacterium tuberculosis Infection in Mice. J Immunol 199(8):2815-2822, 2017. e-Pub 2017. PMID: 28855309.
- Ritthipichai K, Haymaker CL, Martinez M, Aschenbrenner A, Yi X, Zhang M, Kale C, Vence LM, Roszik J, Hailemichael Y, Overwijk WW, Varadarajan N, Nurieva R, Radvanyi LG, Hwu P, Bernatchez C. Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. Clin Cancer Res 23(20):6151-6164, 2017. e-Pub 2017. PMID: 28754817.
- Kim BS, Lu H, Ichiyama K, Chen X, Zhang YB, Mistry NA, Tanaka K, Lee YH, Nurieva R, Zhang L, Yang X, Chung Y, Jin W, Chang SH, Dong C. Generation of RORγt+ Antigen-Specific T Regulatory 17 Cells from Foxp3+ Precursors in Autoimmunity. Cell Rep 21(1):195-207, 2017. e-Pub 2017. PMID: 28978473.
- Haymaker C, Yang Y, Wang J, Zou Q, Sahoo A, Alekseev A, Singh D, Ritthipichai K, Hailemichael Y, Hoang ON, Qin H, Schluns KS, Wang T, Overwijk WW, Sun SC, Bernatchez C, Kwak LW, Neelapu SS, Nurieva R. Absence of Grail promotes CD8+ T cell anti-tumour activity. Nat Commun 8(1):239, 2017. e-Pub 2017. PMID: 28798332.
- Venkatasubramanian S, Cheekatla S, Paidipally P, Tripathi D, Welch E, Tvinnereim AR, Nurieva R, Vankayalapati R. IL-21-dependent expansion of memory-like NK cells enhances protective immune responses against Mycobacterium tuberculosis. Mucosal Immunol 10(4):1031-1042, 2017. e-Pub 2017. PMID: 27924822.
- Mandal PK, Morlacchi P, Knight JM, Link TM, Lee GR, Nurieva R, Singh D, Dhanik A, Kavraki L, Corry DB, Ladbury JE, McMurray JS. Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity. J Med Chem 58(22):8970-84, 2015. e-Pub 2015. PMID: 26506089.
- Cao AT, Yao S, Gong B, Nurieva RI, Elson CO, Cong Y. Interleukin (IL)-21 promotes intestinal IgA response to microbiota. Mucosal Immunol 8(5):1072-82, 2015. e-Pub 2015. PMID: 25586558.
- Sahoo A, Alekseev A, Tanaka K, Obertas L, Lerman B, Haymaker C, Clise-Dwyer K, McMurray JS, Nurieva R. Batf is important for IL-4 expression in T follicular helper cells. Nat Commun 6:7997, 2015. e-Pub 2015. PMID: 26278622.
- Tanaka S, Tanaka K, Magnusson F, Chung Y, Martinez GJ, Wang YH, Nurieva RI, Kurosaki T, Dong C. CCAAT/enhancer-binding protein α negatively regulates IFN-γ expression in T cells. J Immunol 193(12):6152-60, 2014. e-Pub 2014. PMID: 25398328.
- Sahoo A, Alekseev A, Obertas L, Nurieva R. Grail controls Th2 cell development by targeting STAT6 for degradation. Nat Commun 5:4732, 2014. e-Pub 2014. PMID: 25145352.
- Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, Qian J, Hailemichael Y, Nurieva R, Dwyer KC, Roth J, Yi Q, Overwijk WW, Kwak LW. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med 20(6):676-81, 2014. e-Pub 2014. PMID: 24859530.
- Liu X, Chen X, Zhong B, Wang A, Wang X, Chu F, Nurieva RI, Yan X, Chen P, van der Flier LG, Nakatsukasa H, Neelapu SS, Chen W, Clevers H, Tian Q, Qi H, Wei L, Dong C. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature 507(7493):513-8, 2014. e-Pub 2014. PMID: 24463518.
- Blonska M, Joo D, Nurieva RI, Zhao X, Chiao P, Sun SC, Dong C, Lin X. Activation of the transcription factor c-Maf in T cells is dependent on the CARMA1-IKKβ signaling cascade. Sci Signal 6(306):ra110, 2013. e-Pub 2013. PMID: 24345681.
- Glasmacher E, Agrawal S, Chang AB, Murphy TL, Zeng W, Vander Lugt B, Khan AA, Ciofani M, Spooner CJ, Rutz S, Hackney J, Nurieva R, Escalante CR, Ouyang W, Littman DR, Murphy KM, Singh H. A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes. Science 338(6109):975-80, 2012. e-Pub 2012. PMID: 22983707.
- Liu X, Yan X, Zhong B, Nurieva RI, Wang A, Wang X, Martin-Orozco N, Wang Y, Chang SH, Esplugues E, Flavell RA, Tian Q, Dong C. Bcl6 expression specifies the T follicular helper cell program in vivo. J Exp Med 209(10):1841-52, S1-24, 2012. e-Pub 2012. PMID: 22987803.
- Ma Q, Li D, Nurieva R, Patenia R, Bassett R, Cao W, Alekseev AM, He H, Molldrem JJ, Kroll MH, Champlin RE, Sale GE, Afshar-Kharghan V. Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation. Biol Blood Marrow Transplant 18(8):1174-81, 2012. e-Pub 2012. PMID: 22664751.
- Bollig N, Brüstle A, Kellner K, Ackermann W, Abass E, Raifer H, Camara B, Brendel C, Giel G, Bothur E, Huber M, Paul C, Elli A, Kroczek RA, Nurieva R, Dong C, Jacob R, Mak TW, Lohoff M. Transcription factor IRF4 determines germinal center formation through follicular T-helper cell differentiation. Proc Natl Acad Sci U S A 109(22):8664-9, 2012. e-Pub 2012. PMID: 22552227.
- Nurieva RI, Podd A, Chen Y, Alekseev AM, Yu M, Qi X, Huang H, Wen R, Wang J, Li HS, Watowich SS, Qi H, Dong C, Wang D. STAT5 protein negatively regulates T follicular helper (Tfh) cell generation and function. J Biol Chem 287(14):11234-9, 2012. e-Pub 2012. PMID: 22318729.
- Wang X, Zhang Y, Yang XO, Nurieva RI, Chang SH, Ojeda SS, Kang HS, Schluns KS, Gui J, Jetten AM, Dong C. Transcription of Il17 and Il17f is controlled by conserved noncoding sequence 2. Immunity 36(1):23-31, 2012. e-Pub 2012. PMID: 22244845.
- Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, Wang YH, Lim H, Reynolds JM, Zhou XH, Fan HM, Liu ZM, Neelapu SS, Dong C. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med 17(8):983-8, 2011. e-Pub 2011. PMID: 21785430.
- Xu T, Wang X, Zhong B, Nurieva RI, Ding S, Dong C. Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein. J Biol Chem 286(26):22707-10, 2011. e-Pub 2011. PMID: 21566134.
- Nurieva RI, Zheng S, Jin W, Chung Y, Zhang Y, Martinez GJ, Reynolds JM, Wang SL, Lin X, Sun SC, Lozano G, Dong C. The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity 32(5):670-80, 2010. e-Pub 2010. PMID: 20493730.
- Reynolds JM, Pappu BP, Peng J, Martinez GJ, Zhang Y, Chung Y, Ma L, Yang XO, Nurieva RI, Tian Q, Dong C. Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity 32(5):692-702, 2010. e-Pub 2010. PMID: 20434372.
- Yang XO, Angkasekwinai P, Zhu J, Peng J, Liu Z, Nurieva R, Liu X, Chung Y, Chang SH, Sun B, Dong C. Requirement for the basic helix-loop-helix transcription factor Dec2 in initial TH2 lineage commitment. Nat Immunol 10(12):1260-6, 2009. e-Pub 2009. PMID: 19881507.
- Zhang Y, Reynolds JM, Chang SH, Martin-Orozco N, Chung Y, Nurieva RI, Dong C. MKP-1 is necessary for T cell activation and function. J Biol Chem 284(45):30815-24, 2009. e-Pub 2009. PMID: 19748894.
- Nurieva RI, Chung Y, Martinez GJ, Yang XO, Tanaka S, Matskevitch TD, Wang YH, Dong C. Bcl6 mediates the development of T follicular helper cells. Science 325(5943):1001-5, 2009. e-Pub 2009. PMID: 19628815.
- Wang Y, Li D, Nurieva R, Yang J, Sen M, Carreño R, Lu S, McIntyre BW, Molldrem JJ, Legge GB, Ma Q. LFA-1 affinity regulation is necessary for the activation and proliferation of naive T cells. J Biol Chem 284(19):12645-53, 2009. e-Pub 2009. PMID: 19297325.
- Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, Tian Q, Dong C. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30(4):576-87, 2009. e-Pub 2009. PMID: 19362022.
- Liu X, Alexiou M, Martin-Orozco N, Chung Y, Nurieva RI, Ma L, Tian Q, Kollias G, Lu S, Graf D, Dong C. Cutting edge: A critical role of B and T lymphocyte attenuator in peripheral T cell tolerance induction. J Immunol 182(8):4516-20, 2009. e-Pub 2009. PMID: 19342624.
- Nurieva R, Yang XO, Chung Y, Dong C. Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J Immunol 182(5):2565-8, 2009. e-Pub 2009. PMID: 19234148.
- Yamazaki T, Yang XO, Chung Y, Fukunaga A, Nurieva R, Pappu B, Martin-Orozco N, Kang HS, Ma L, Panopoulos AD, Craig S, Watowich SS, Jetten AM, Tian Q, Dong C. CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol 181(12):8391-401, 2008. e-Pub 2008. PMID: 19050256.
- Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, Shah B, Chang SH, Schluns KS, Watowich SS, Feng XH, Jetten AM, Dong C. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29(1):44-56, 2008. e-Pub 2008. PMID: 18585065.
- Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, Wang YH, Watowich SS, Jetten AM, Tian Q, Dong C. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29(1):138-49, 2008. e-Pub 2008. PMID: 18599325.
- Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, Wang YH, Schluns KS, Broaddus RR, Zhu Z, Dong C. Regulation of inflammatory responses by IL-17F. J Exp Med 205(5):1063-75, 2008. e-Pub 2008. PMID: 18411338.
- Chung Y, Nurieva R, Esashi E, Wang YH, Zhou D, Gapin L, Dong C. A critical role of costimulation during intrathymic development of invariant NK T cells. J Immunol 180(4):2276-83, 2008. e-Pub 2008. PMID: 18250436.
- Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, Watowich SS, Tian Q, Jetten AM, Dong C. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28(1):29-39, 2008. e-Pub 2008. PMID: 18164222.
- Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, Dong C. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448(7152):480-3, 2007. e-Pub 2007. PMID: 17581589.
- Nurieva RI, Chuvpilo S, Wieder ED, Elkon KB, Locksley R, Serfling E, Dong C. A costimulation-initiated signaling pathway regulates NFATc1 transcription in T lymphocytes. J Immunol 179(2):1096-103, 2007. e-Pub 2007. PMID: 17617602.
- Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 282(13):9358-63, 2007. e-Pub 2007. PMID: 17277312.
- Yu XZ, Liang Y, Nurieva RI, Guo F, Anasetti C, Dong C. Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells. J Immunol 176(12):7394-401, 2006. e-Pub 2006. PMID: 16751384.
- Nurieva R, Thomas S, Nguyen T, Martin-Orozco N, Wang Y, Kaja MK, Yu XZ, Dong C. T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J 25(11):2623-33, 2006. e-Pub 2006. PMID: 16724117.
- Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6(11):1133-41, 2005. e-Pub 2005. PMID: 16200068.
- Nurieva RI, Mai XM, Forbush K, Bevan MJ, Dong C. B7h is required for T cell activation, differentiation, and effector function. Proc Natl Acad Sci U S A 100(24):14163-8, 2003. e-Pub 2003. PMID: 14615582.
- Dong C, Nurieva RI. Regulation of immune and autoimmune responses by ICOS. J Autoimmun 21(3):255-60, 2003. e-Pub 2003. PMID: 14599850.
- Nurieva RI, Duong J, Kishikawa H, Dianzani U, Rojo JM, Ic H, Flavell RA, Dong C. Transcriptional regulation of th2 differentiation by inducible costimulator. Immunity 18(6):801-11, 2003. e-Pub 2003. PMID: 12818161.
- Nurieva RI, Treuting P, Duong J, Flavell RA, Dong C. Inducible costimulator is essential for collagen-induced arthritis. J Clin Invest 111(5):701-6, 2003. e-Pub 2003. PMID: 12618524.
- Lepikhova TN, Navolotskaya EV, Zargarova TA, Nurieva RI, Lipkin VM, Zav'yalov VP. Influence of synthetic peptide corresponding to the ACTH-like sequence of human immunoglobulin G1 on proliferation of lymphoblastoid cells. Peptides 21(3):353-7, 2000. e-Pub 2000. PMID: 10793216.
- Navolotskaya EV, Zargarova TA, Lepikhova TN, Turobov VI, Nurieva RI, Malkova NV, Lipkin VM, Zav'yalov VP. Study of immunosuppressive activity of a synthetic decapeptide corresponding to an ACTH-like sequence of human immunoglobulin G1. Biochemistry (Mosc) 64(7):758-64, 1999. e-Pub 1999. PMID: 10424898.
- Nurieva RI, Navolotskaya EV, Lepikhova TN, Kostanyan IA, Lipkin VM. A Study of L-Glutamate Binding on Murine Peritoneal Macrophages and Its Influence on the Activity of These Cells. Russ J Immunol 3(3-4):270-273, 1998. e-Pub 1998. PMID: 12687106.
- Kostanian IA, Nurieva RI, Lepikhova TN, Astapova MV, Navolotskaia EV, Zavialov VP, Lipkin VM. [Appearance of glutamate receptors on the surface of HL-60 cells upon differentiation]. Bioorg Khim 24(6):468-70, 1998. e-Pub 1998. PMID: 9702357.
- Kostanyan IA, Nurieva RI, Navolotskaya EV, Astapova MV, Dranitsina SM, Bogachuk AP, Zav'yalov VP, Lipkin VM. Influence of L-glutamic acid on binding of interleukin-1beta, tumour necrosis factor-alpha and interleukin-6 to HL-60 cells. Immunol Lett 62(1):9-13, 1998. e-Pub 1998. PMID: 9672141.
- Kostanian IA, Nurieva RI, Navolotskaia EV, Astapova MV, Dranitsyna SM, Zav'ialov VP, Lipkin VM. [Mechanism of differentiating action of L-glutamic acid on HL-60 cells]. Mol Biol (Mosk) 32(1):148-53, 1998. e-Pub 1998. PMID: 9566262.
- Kostanian IA, Nurieva RI, Novolotskaia EV, Astapova MV, Dranitsyna SM, Zav'ialov VP, Lipkin VM. [Effect of L-glutamic acid on the reception of cytokines by HL-60 cells]. Bioorg Khim 24(1):3-9, 1998. e-Pub 1998. PMID: 9551194.
- Kostanyan IA, Navolotskaya EV, Nurieva RI, Zav'ialov VP, Lipkin VM. [Interaction of L-glutamic acid with human T-lymphocytes]. Bioorg Khim 23(10):805-8, 1997. e-Pub 1997. PMID: 9490616.
- Kostanyan IA, Merkulova MI, Navolotskaya EV, Nurieva RI. Study of interaction between L-glutamate and human blood lymphocytes. Immunol Lett 58(3):177-80, 1997. e-Pub 1997. PMID: 9293400.
- Kostanyan IA, Navolotskaya EV, Nurieva RI. Identification of Binding Sites for L-Glutamate on T Lymphocytes. Russ J Immunol 2(2):135-137, 1997. e-Pub 1997. PMID: 12687068.
- Abdrasilov BS, YuA K, Nurieva RI, Dedkova EN, Leonteva GA, Park HJ, Zinchenko VP. The effect of total saponins from Panax Ginseng C.A. Meyer on the intracellular signalling system in Ehrlich ascites tumor cells. Biochem Mol Biol Int 38(3):519-26, 1996. e-Pub 1996. PMID: 8829611.
Invited Articles
- Haymaker CL, Hailemichael Y, Yang Y, Nurieva R. In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model. J Vis Exp(129), 2017. e-Pub 2017. PMID: 29286361.
- Wali S, Sahoo A, Puri S, Alekseev A, Nurieva R. Insights into the development and regulation of T follicular helper cells. Cytokine 87:9-19, 2016. e-Pub 2016. PMID: 27339151.
- Sahoo A, Wali S, Nurieva R. T helper 2 and T follicular helper cells: Regulation and function of interleukin-4. Cytokine Growth Factor Rev 30:29-37, 2016. e-Pub 2016. PMID: 27072069.
- Nurieva R, Wang J, Sahoo A. T-cell tolerance in cancer. Immunotherapy 5(5):513-531, 2013. e-Pub 2013. PMID: 23638746.
Review Articles
- López Moreno, SF, Lenz, SA, Casso-Chapa, B, Paniagua Bojorges, A, Kim, JH, Palaskas, NL, Nead, KT, Samanthapudi, VS, Mejia, G, Hoang, ON, Lee, J, Lin, SH, Herrmann, J, Wang, G, Yusuf, SW, Iliescu, C, Beinart, N, Manisty, C, Ushio-Fukai, M, Fukai, T, Ameri, P, Nurieva, R, Hildebrandt, MA, Schadler, KL, Koutroumpakis, E, Kotla, S, Le, NT, Abe, J. SHP2. Antioxidants 14(12), 2025. e-Pub 2025. PMID: 41462587.
- Turner N, Colunga-Minutti J, Alekseev S, Jenq RR, Nurieva R. Link between dysbiosis and cancer: Contributing mechanisms and factors. Int Rev Cell Mol Biol 394:43-78, 2025. e-Pub 2025. PMID: 40623768.
- Turner N, Hamidi S, Ouni R, Rico R, Henderson YC, Puche M, Alekseev S, Colunga-Minutti JG, Zafereo ME, Lai SY, Kim ST, Cabanillas ME, Nurieva RI. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Front Immunol 15:1369780, 2024. e-Pub 2024. PMID: 38868771.
- Qin L, Waseem TC, Sahoo A, Bieerkehazhi S, Zhou H, Galkina EV, Nurieva R. Insights Into the Molecular Mechanisms of T Follicular Helper-Mediated Immunity and Pathology. Front Immunol 9:1884, 2018. e-Pub 2018. PMID: 30158933.
- Liu X, Nurieva RI, Dong C. Transcriptional regulation of follicular T-helper (Tfh) cells. Immunol Rev 252(1):139-45, 2013. e-Pub 2013. PMID: 23405901.
- Nurieva RI, Liu X, Dong C. Molecular mechanisms of T-cell tolerance. Immunol Rev 241(1):133-44, 2011. e-Pub 2011. PMID: 21488895.
- Nurieva RI, Chung Y. Understanding the development and function of T follicular helper cells. Cell Mol Immunol 7(3):190-7, 2010. e-Pub 2010. PMID: 20383172.
- Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev 229(1):88-100, 2009. e-Pub 2009. PMID: 19426216.
- Nurieva RI. Regulation of immune and autoimmune responses by ICOS-B7h interaction. Clin Immunol 115(1):19-25, 2005. e-Pub 2005. PMID: 15870016.
- Dong C, Nurieva RI, Prasad DV. Immune regulation by novel costimulatory molecules. Immunol Res 28(1):39-48, 2003. e-Pub 2003. PMID: 12947223.
Other Articles
- Kim ST, Chu Y, Misoi MW, Suarez-Almazor M, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang RJ, Shah AY, Tannir NM, Campbell M, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Hassan NA, Tawbi H, Hwu P, Oliva IC, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R Author Correction. Nature communications 15(1), 2024. PMID: 38965214.
Editorials
- Nurieva RI, Dong C. (IL-)12 and 21: a new kind of help in the follicles. Immunol Cell Biol 87(8):577-8, 2009. PMID: 19907426.
- Nurieva RI, Dong C. Keeping autoimmunity in check: how to control a Th17 cell controller. Immunity 29(6):841-3, 2008. PMID: 19100696.
Abstracts
- Nurieva R. Immune-checkpoint induced inflammatory arthritis: underlying mechanisms and therapeutic strategies. The 18th International Congress of Immunology, Cape Town, South Africa, 2023. e-Pub 2023.
- Nurieva R. Inflammatory arthritis induced by immune checkpoint inhibitors: underlying mechanisms and therapeutic strategies. 11th Annual Meeting of International Cytokine & Interferon Society (ICIS), Cytokines 2023, Athens, Greece, 2023. e-Pub 2023.
- Nurieva R. Role of T follicular helper cells in anti-tumor immunity. Keystone Symposia: T and B Cell Collaboration in Germinal Centers and Beyond. Whistler, BC, Canada, 2023. e-Pub 2023.
- Nurieva R. Mechanism underlying immune-related adverse events (irAEs) in cancer patients receiving ICI therapy. 4th International Conference on Cell and Experimental Biology, Houston, TX, 2023. e-Pub 2023.
- Ouni R, Henderson Y, Chen Y, Turner N, Padron W, Dadbin A, McBeath Fujiwara E, Wang JR, Cabanillas M, Dadu R, Hofmann MC, Zafereo ME, Kim ST, Lai S, Nurieva R. Characterization of altered immunity in anaplastic thyroid cancer. Leading Edge of Cancer Research Symposium, Houston, TX (The University of Texas MD Anderson Cancer Center), 2022. e-Pub 2022.
- Kunnimalaiyaan M, Dadbin A, Henderson Y, McBeath Fujiwara E, Stephan C, Nurieva R, Busaidy NL, Wang JR, Lai S, Cabanillas M, Zafereo ME, Dadu R, Hofmann MC. Therapeutic potential of ralimetinib, a p38/MAPK14 inhibitor, in anaplastic thyroid cancer. Leading Edge of Cancer Research Symposium, Houston, TX (The University of Texas MD Anderson Cancer Center), 2022. e-Pub 2022.
- Nurieva R. Role of T follicular helper cells in anti-tumor immunity. 10th Annual Meeting of International Cytokine & Interferon Society (ICIS), Cytokines 2022, Big Island, Hawaii, USA, 2022. e-Pub 2022.
- Nurieva R. Role of Grail in intestinal inflammation. American Association of Immunologists (AAI), 2022. e-Pub 2022.
- Nurieva R. Role of E3 ubiquitin ligase GRAIL in intestinal homeostasis. 9th Annual Meeting of International Cytokine & Interferon Society (ICIS), Cytokines 2021, Cardiff, Wales, UK, 2021. e-Pub 2021.
- Nurieva R. Transcriptional regulation of IL-21 expression in T follicular helper cells. 8th Annual Meeting of International Cytokine & Interferon Society (ICIS), 2020. e-Pub 2020.
- Nurieva R. Therapeutic potential of follicular helper T cells for melanoma treatment. American Association of Immunologists (AAI), 2020. e-Pub 2020.
- Nurieva R. Role of Tfh cell-derived cytokines in anti-tumor immunity. 7th Annual Meeting of International Cytokine & Interferon Society (ICIS), Vienna, Austria, 2019. e-Pub 2019.
- Nurieva R. Role of Tfh cells in the antitumor immunity, symposium. Follicular Helper T cells: 10 years and beyond, 2019. e-Pub 2019.
- Nurieva R. Function of follicular helper T cells in anti-tumor immunity. Immunology, American Association of Immunologists (AAI), 2019. e-Pub 2019.
- Kim ST, Tayar J, Lu H, Suarez-Almazor M, Rodriguez E, Neelapu SS, Wang J, Shah A, Tannir N, Gibbons D, Garcia-Manero G, Tawbi HA, Hwu P, Diab A, Nurieva R. Expansion of IL-17 producing CD4+ T cells in synovial fluid from patients with arthritis resulting from combination therapy of PD-1 and CTLA-4 inhibitors. Keystone Symposium - Uncovering Mechanisms of Immune-Based Therapy in Cancer and Autoimmunity, Breckenridge, CO, 2019. e-Pub 2019.
- Nurieva R. Role of Grail in B cell activation and tolerance. 5th European Congress of Immunology, Amsterdam, Netherlands, 2018. e-Pub 2018.
- Nurieva R. Role of E3 ubiquitin ligase GRAIL in B cell activation and tolerance. Keystone Symposium - B Cells: Mechanisms in Immunity and Autoimmunity, Dresden, Germany, 2018. e-Pub 2018.
- Nurieva R, Bieerkehazhi S, Waseem TC, Hoang ON, Sahoo A, Alekseev A, Galkina E. Role of E3 ubiquitin ligase GRAIL in B cell activation and tolerance. American Association of Immunologists (AAI) Annual Meeting, Austin, TX, 2018. e-Pub 2018.
- Nurieva R, Sahoo A, Alekseev A. STAT1 is essential for IL-21 expression in T follicular helper cells. Kanazawa, Japan, 2017. e-Pub 2017.
- Nurieva R. Absnce of grail promotes CD8+ T cell anti-tumor activity. Tumor & Cancer Immunology and Immunotherapy, Chicago, IL, 2017. e-Pub 2017.
- Nurieva R, Sahoo A, Alekseev A. STAT1 is required for Tfh lineage maintenance through regulation of IL-21 expression. Immunology 2017, Washington, DC, 2017. e-Pub 2017.
- Nurieva R, Sahoo A, Alekseev A. STAT1 is required for Tfh lineage maintenance through regulation of IL-21 expression. Keystone Symposia, Whistler, Canada, 2017. e-Pub 2017.
- Nurieva RI, Wang J, Haymaker C, Alekseev A, Bernatchez C, Neelapu SS. Absence of grail in CD8+ T cells confers spontaneous tumor regression. J Immunology 196:212-16, 2016. e-Pub 2016.
- Nurieva R. Batf is essential for IL-4 expression in T follicular helper cells and for their pro-allergic function. Keystone Symposia, T Follicular Helper Cells and Germinal Centers, Montreal, Canada, 2016. e-Pub 2016.
- Nurieva R. 4th regulation of Th2 cell development by Grail. European Congress of Immunology, Vienna, Austria, 2015. e-Pub 2015.
- Nurieva R. BATF is essential for IL-4 expression in T follicular helper cells. Presented at the 4th International Conference and Exhibition on Immunology, Houston, TX, 2015. e-Pub 2015.
- Nurieva R. Transcriptional regulation of IL-4 expression in T follicular helper cells. Immunology, American Association of Immunologists (AAI), New Orleans, LA, 2015. e-Pub 2015.
- Nurieva R. Transcriptional regulation of IL-4 expression in T follicular helper T cells. Annual Meeting of International Cytokine Society (ICS), Cytokines 2015 - Symphonies in Health and Disease, Bamberg, Germany, 2015. e-Pub 2015.
- Sahoo A, Lerman B, Alekseev A, Nurieva R. E3 ligases in T helper 2-mediated pathogenesis. Immunome Res 11(1), 2014. e-Pub 2014.
- Nurieva RI. Role of GRAIL in T cell function. Presented at The University of Texas Medical Branch, Galveston, TX, 2014. e-Pub 2014.
- Nurieva RI. E3 ubiquitin ligases in T cell tolerance. Presented at The University of Texas Health Science Center at Tyler, Tyler, TX, 2013. e-Pub 2013.
- Nurieva R, Wang J, Alekseev A. Essential role of E3 ubiquitin ligase activity of GRAIL in T cell functions. Presented at Immunology 2013, 100th Annual Meeting of the American Association of Immunologists (AAI), Honolulu, HI, 2013. e-Pub 2013.
- Nurieva R, Podd A, Chen Y, Alekseev AM Wang J, Dong C, Wang D. STAT5 controls Tfh development. Presented at: Immunology 2012, 99th Annual Meeting of the American Association of Immunologists (AAI), Boston, MA, 2012. e-Pub 2012.
- Nurieva RI, Lozano G, Dong C. Regulation of naive T cell tolerance and regulatory T cell function by GRAIL. Presented at the American Association of Immunologists (AAI) Annual Meeting, San Francisco, CA, 2011. e-Pub 2011.
- Nurieva RI, Zheng S, Jin W, S-C S, Lozano G, Dong C. A critical role of GRAIL in T cell activation and tolerance. Presented at the American Association of Immunologists (AAI) Annual Meeting - Immunology 2010, 2010. e-Pub 2010.
- Nurieva RI. Developmental requirements of T follicular helper cell. Biotechnology Symposium '09, Atlanta, GA, 2009. e-Pub 2009.
- Nurieva RI, Chung Y, Dong C. Developmental requirements of T follicular helper cells. American Association of Immunologists (AAI) Annual Meeting, Seattle, WA, 2009. e-Pub 2009.
- Nurieva R, Chung Y, Yang X, Dong C. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 17 cell lineage. Keystone Symposia: TH17 Cells in Health and Disease, Vancouver, BC, 2009. e-Pub 2009.
- Nurieva RI, Chung Y, Yang XO, Dong C. Regulation of T follicular helper cell development. Lupus Autoimmunity: Mechanisms and Immune Regulation, La Jolla, CA, 2008. e-Pub 2008.
- Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, Dong C. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. 15th Annual Meeting of the International Cytokine Society (ICS), San Francisco, CA, 2007. e-Pub 2007.
- Nurieva RI. T cells function and tolerance is controlled by costimulatory signals. Arthritis Research Conference, Stone Mountain, GA, 2007. e-Pub 2007.
- Nurieva RI, Thomas S, Ngyuen T, Martin-Orozoco N, Wang Y, Kaja MK, X-Zh Y, Dong C. Costimulation requirements for T cell activation and tolerance: Gene expression and signaling in the immune system. Cold Spring Harbor, NY, 2006. e-Pub 2006.
- Nurieva RI, Chuvpilo S, Elkon K, Locksley R, Serfling E, Dong C. Synergy and redundancy of costimulatory pathways in CD4 and CD8 cells. Arthritis Research Conference, Stone Mountain, GA, 2005. e-Pub 2005.
- Nurieva RI, Chuvpilo S, Elkon K, Locksley R, Serfling E, Dong C. Synergy and redundancy of costimulatory pathways in CD4 and CD8 cells. American Association of Immunologists (AAI) Annual Meeting, San Diego, CA, 2005. e-Pub 2005.
- Nurieva RI, Forbush K, Bevan MJ, Flavell RA, Dong C. Regulation of immune and autoimmune responses by ICOS-B7h interaction. 12th International Congress of Immunology and 4th Annual Conference of Federation of Clinical Immunology Societies (FOCIS), Montreal, Canada W11.29:38C, 2004. e-Pub 2004.
Book Chapters
- Nurieva R, Divenko M, Kim ST. Cancer immunology and the evolution of immunotherapy, 3-29, 2021.
- Nurieva R, Kim S, Divenko M. Cancer immunology and the evolution of immunotherapy. In: Rheumatic Diseases and Syndromes Inducted by Cancer Immunotherapy: A Handbook for Diagnosis and Management. Springer, Cham. https://doi.org/10.1007/978-3-030-56824-5_1, 2021.
- Martinez GJ, Nurieva RI, Yang XO, Dong C. Regulation and function of proinflammatory TH17 cells. In: Ann N Y Acad Sci. Wiley, 188-211, 2008.
- Dong C, Nurieva RI, Martin-Orozco N. Immune regulation and immunotherapy of autoimmune disease. In: Costimulation Regulation of Immune Tolerance and Autoimmunity. Springer US, Life Sciences, 121-138, 2007.
- Dong C, Chang S, Yang X, Nurieva R. Inflammatory T cells: regulation, function and pathological roles in disease. In: Effector CD4 T Cell Subsets in Health and Disease. Research Signpost, 65-84, 2007.
Patient Reviews
CV information above last modified August 14, 2026